American Journal of Clinical Dermatology

, Volume 20, Issue 1, pp 31–40 | Cite as

Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis

  • Hsi Yen
  • Ching-Chi ChiEmail author
Systematic Review



The relationship between psoriasis and vitiligo has not been previously confirmed, and we therefore aimed to investigate this association.


We conducted a search of the MEDLINE and EMBASE electronic databases on 22 January 2018 for case–control, cross-sectional, and cohort studies examining the association between psoriasis and vitiligo. A customized Newcastle–Ottawa Scale was used to assess the risk of bias of the included studies. We performed a random effects meta-analysis to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs) for case–control and cross-sectional studies.


Of 2453 citations identified from the literature search, 10 case–control/cross-sectional studies with a total of 120,866 psoriasis cases and 79,907 vitiligo cases were included in our study. Four of these studies were rated as high risk of bias. We found a significantly increased odds for vitiligo in psoriasis patients (summary OR 2.29, 95% CI 1.56–3.37, studies = 7), as well as a significantly elevated odds for psoriasis in vitiligo patients (summary OR 3.43, 95% CI 1.86–6.33, studies = 4).


Our meta-analysis showed that psoriasis and vitiligo are associated with each other. Several studies had a high risk of bias, and further investigation is needed to confirm this association and amplify treatment options.


Compliance with Ethical Standards


No funding was received for the conduct of this study or the preparation of this article.

Conflict of interest

Hsi Yen and Ching-Chi Chi have no conflicts of interest directly relevant to the content of this article.

Supplementary material

40257_2018_394_MOESM1_ESM.pdf (62 kb)
Supplementary material 1 (PDF 62 kb)


  1. 1.
    Michalek I, Loring B, John S. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.CrossRefGoogle Scholar
  2. 2.
    Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.CrossRefGoogle Scholar
  3. 3.
    Damiani G, Berti E, Pigatto P, Franchi C, Asa’ad F. Benchmarking stem cells and transplantation in psoriasis. J Stem Cell Res Ther. 2018;8(3):416.Google Scholar
  4. 4.
    Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.CrossRefGoogle Scholar
  5. 5.
    Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.CrossRefGoogle Scholar
  6. 6.
    Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.CrossRefGoogle Scholar
  7. 7.
    Wu JJ, Nguyen TU, Poon KYT, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924–30.CrossRefGoogle Scholar
  8. 8.
    Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40.CrossRefGoogle Scholar
  9. 9.
    Blegvad C, Egeberg A, Tind Nielsen TE, Gislason GH, Zachariae C, Nybo Andersen AM, et al. Autoimmune disease in children and adolescents with psoriasis: A cross-sectional study in Denmark. Acta Derm Venereol. 2017;97(10):1225–9.CrossRefGoogle Scholar
  10. 10.
    Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151–7.CrossRefGoogle Scholar
  11. 11.
    Sharquie KE, Salman HA, Yaseen AK. Psoriasis and vitiligo are close relatives. Clin Cosmet Investig Dermatol. 2017;10:341–5.CrossRefGoogle Scholar
  12. 12.
    Zander N, Schäfer I, Radtke M, Jacobi A, Heigel H, Augustin M. Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. Arch Dermatol Res. 2017;309(5):349–56.CrossRefGoogle Scholar
  13. 13.
    Chen YT, Chen YJ, Hwang CY, Lin MW, Chen TJ, Chen CC, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362–9.CrossRefGoogle Scholar
  14. 14.
    Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015;56(3):719–25.CrossRefGoogle Scholar
  15. 15.
    Teulings HE, Ceylan E, Overkamp M, Vrijman C, Bos JD, Nijsten TE, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years. Br J Dermatol. 2016;175(4):821–4.CrossRefGoogle Scholar
  16. 16.
    Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr Med Res Opin. 2006;22(5):989–1000.CrossRefGoogle Scholar
  17. 17.
    Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.Google Scholar
  18. 18.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.CrossRefGoogle Scholar
  19. 19.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2006. Accessed 6 Feb 2018.
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefGoogle Scholar
  21. 21.
    Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRefGoogle Scholar
  23. 23.
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRefGoogle Scholar
  24. 24.
    Sawchuk M, Spano F, Loo WJ, Guenther L. The coexistence of psoriasis and vitiligo: a review. J Cutan Med Surg. 2012;16(5):300–5.CrossRefGoogle Scholar
  25. 25.
    Sandhu K, Kaur I, Kumar B. Psoriasis and vitiligo. J Am Acad Dermatol. 2004;51(1):149–50.CrossRefGoogle Scholar
  26. 26.
    Zhernakova A, Van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10(1):43–55.CrossRefGoogle Scholar
  27. 27.
    Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55(5):443–52.CrossRefGoogle Scholar
  28. 28.
    Martinon F, Gaide O, Pétrilli V, Mayor A, Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007;29(3):213–29.CrossRefGoogle Scholar
  29. 29.
    Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356(12):1216–25.CrossRefGoogle Scholar
  30. 30.
    Carlström M, Ekman AK, Petersson S, Söderkvist P, Enerbäck C. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 2012;21(12):932–7.CrossRefGoogle Scholar
  31. 31.
    Johansen C, Moeller K, Kragballe K, Iversen L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol. 2007;127(12):2857–64.CrossRefGoogle Scholar
  32. 32.
    Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 expression is upregulated in lesional psoriatic skin. J Invest Dermatol. 2011;131(3):670–6.CrossRefGoogle Scholar
  33. 33.
    Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170(4):816–23.CrossRefGoogle Scholar
  34. 34.
    Zhu K-J, Lv Y-M, Yin X-Y, Wang Z-X, Sun L-D, He S-M, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011;6(11):e23089.CrossRefGoogle Scholar
  35. 35.
    Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.CrossRefGoogle Scholar
  36. 36.
    Taher Z, Lauzon G, Maguiness S, Dytoc M. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol. 2009;161(3):654–9.CrossRefGoogle Scholar
  37. 37.
    Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–50.CrossRefGoogle Scholar
  38. 38.
    Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, et al. The role of IL-17 in vitiligo: a review. Autoimmun Rev. 2016;15(4):397–404.CrossRefGoogle Scholar
  39. 39.
    Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2):256–60.CrossRefGoogle Scholar
  40. 40.
    Bassiouny D, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292–7.CrossRefGoogle Scholar
  41. 41.
    Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology. 1996;193(1):65–6.CrossRefGoogle Scholar
  42. 42.
    Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon-induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010;49(7):829–33.CrossRefGoogle Scholar
  43. 43.
    Afshar M, Martinez A, Gallo R, Hata T. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27(6):771–8.CrossRefGoogle Scholar
  44. 44.
    Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38–47.CrossRefGoogle Scholar
  45. 45.
    Seçkin D, Durusoy Ç, Şahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21(5):577–9.CrossRefGoogle Scholar
  46. 46.
    Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol. 2008;20(4):401–7.CrossRefGoogle Scholar
  47. 47.
    Bertolotti A, Boniface K, Vergier B, Mossalayi D, Taieb A, Ezzedine K, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407.CrossRefGoogle Scholar
  48. 48.
    Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–44.CrossRefGoogle Scholar
  49. 49.
    Kuo CM, Tung TH, Wang SH, Chi CC. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(3):355–62.CrossRefGoogle Scholar
  50. 50.
    Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton P. Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol. 2015;173(6):1544–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of DermatologyChang Gung Memorial HospitalTaoyuanTaiwan
  2. 2.College of MedicineChang Gung UniversityTaoyuanTaiwan

Personalised recommendations